Pennant Group 過去の業績
過去 基準チェック /36
Pennant Groupは、平均年間39.2%の収益成長を遂げていますが、 Healthcare業界の収益は、年間 成長しています。収益は、平均年間11.9% 19.9%収益成長率で 成長しています。 Pennant Groupの自己資本利益率は9.5%であり、純利益率は2.9%です。
主要情報
39.19%
収益成長率
35.28%
EPS成長率
| Healthcare 業界の成長 | 8.50% |
| 収益成長率 | 19.93% |
| 株主資本利益率 | 9.51% |
| ネット・マージン | 2.93% |
| 前回の決算情報 | 30 Jun 2026 |
最近の業績更新
Recent updates
ナラティブ更新 • Aug 14
PNTG: Home Health And Hospice Expansion Plus AI Investments Are Expected To Support Upside
Pennant Group’s updated analyst price target has moved higher by about $2.83 to roughly $46.33, with analysts pointing to stronger Q2 performance, improving home health and hospice margins, and sector demand trends as key supports for the change. Analyst Commentary Recent research on Pennant Group focuses on how Q2 execution, margin trends, and sector demand expectations feed into updated valuation views.
ナラティブ更新 • Jul 30
PNTG: Sector Demand Tailwinds And Index Inclusion Will Support Future Upside
The Pennant Group analyst price target has moved from $40 to $49 as analysts point to updated assumptions on revenue growth, profit margins, and sector demand trends to support the higher valuation range. Analyst Commentary on Pennant Group Recent research updates on Pennant Group highlight a more constructive tone from bullish analysts who are revisiting their valuation work ahead of upcoming earnings.ナラティブ更新 • Jul 16
PNTG: Sector Tailwinds And Tech Investments Are Expected To Support Steady Upside
The analyst price target for Pennant Group has increased from $40.83 to $43.50. Analysts attribute this change to supportive sector trends in healthcare services, anticipated demand for care, and ongoing investments in growth and technology, which are key drivers behind their updated assumptions.ナラティブ更新 • Jul 02
PNTG: Q1 Senior Health Momentum And Expansion Are Expected To Support Upside
The Pennant Group analyst price target has increased by about $2.70 to roughly $40.83. Analysts attribute the change to updated views on fair value, profitability, and valuation multiples, following recent research from firms that raised their targets by $2, $3, and $6.分析記事 • Jun 21
Pennant Group (PNTG) Stock Could Be 12.4% Undervalued After Q1 Revenue Beat
Pennant Group (PNTG) is back in focus after reporting quarterly revenue growth of more than 35% year over year, alongside higher net profit, beating analyst expectations and drawing fresh attention to its decentralized operating model. See our latest analysis for Pennant Group. The recent Q1 surprise and focus on Pennant Group’s decentralized model come against a backdrop of building momentum, with a year to date share price return of 20.16% and a 3 year total shareholder return of 174.55%,...
ナラティブ更新 • Jun 18
PNTG: Senior Health Momentum And Hartford Partnership Will Drive Future Stock Upside
Analysts have raised their price target on Pennant Group stock by a combined $11, citing updated views on the company supported by recent research from multiple firms. Analyst Commentary Recent research on Pennant Group stock points to a more nuanced view than the headline price target increases suggest.ナラティブ更新 • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.ナラティブ更新 • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.ナラティブ更新 • Apr 22
PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance
Narrative Update Analysts have nudged Pennant Group's price target higher, with recent moves such as RBC Capital's increase to $41 from $39 contributing to a modest lift in estimated fair value and future P/E assumptions. Analyst Commentary Recent Street research around Pennant Group centers on how the market should weigh its guidance against longer term earnings potential from AMED assets and what that could imply for valuation.ナラティブ更新 • Apr 07
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Guidance
Narrative Update on Pennant Group Analysts have lifted Pennant Group's price targets into a $38 to $41 range, citing long-term earnings potential tied to AMED assets. They also hold a relatively favorable view of Medicare Advantage exposure, even with mixed near term guidance and sector headwinds.ナラティブ更新 • Mar 24
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Outlook
Narrative Update Analysts have recently nudged Pennant Group's average price target higher into the high $30s to low $40s range, citing confidence that the company can gradually realize earnings potential from the AMED assets, even though 2026 adjusted EBITDA guidance sits below earlier expectations. Analyst Commentary Recent research updates show analysts adjusting expectations for Pennant Group while still assigning higher price targets.ナラティブ更新 • Mar 10
PNTG: AMED Earnings Potential Will Offset Tempered Outlook For 2026
Pennant Group's updated fair value estimate edges up to about $37.83 from $37.50 as analysts lift price targets into the high $30s and low $40s, pointing to confidence in long term earnings potential from AMED assets, despite more tempered revenue growth assumptions and a slightly lower future P/E multiple. Analyst Commentary Recent research points to a generally constructive view on Pennant Group, with price targets shifting into the high $30s and low $40s range.ナラティブ更新 • Feb 24
PNTG: Fair Outlook Will Weigh Medicare Advantage Constructiveness Against Policy And Margin Risks
Analysts have raised their price target on Pennant Group from $31 to $38, with the higher fair value of $34 linked to updated views on revenue growth, profit margin, and a higher future P/E multiple in the context of a relatively constructive stance on Medicare Advantage. Analyst Commentary Even with the higher price target range and a constructive stance on Medicare Advantage, some commentary around Pennant Group points to risks that are worth keeping in mind as you weigh the setup.ナラティブ更新 • Feb 10
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Narrative Update on Pennant Group Analysts have raised their price target on Pennant Group to $38 from $31, citing potential upside from home health reimbursement rates even under conservative assumptions, and noting that recent regulatory concerns are already reflected in the shares. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the shares even when they assume conservative home health reimbursement rates, which they view as already reflected in the current valuation.分析記事 • Jan 28
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...ナラティブ更新 • Jan 26
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Analysts have lifted their price target on Pennant Group to US$38 from US$31, citing potential upside from home health reimbursement rates even under conservative assumptions. They also view the current valuation as offering attractive optionality if reimbursement trends improve.ナラティブ更新 • Jan 11
PNTG: Raised Fair Value Framework Will Rely On Home Health Reimbursement Outcomes
Analysts have raised their price target on Pennant Group from $31 to $38, citing updated fair value assumptions of $37.50, a higher future P/E estimate of 27.33, and expectations for stronger revenue growth, while also accounting for a slightly higher discount rate and a modestly lower profit margin outlook. Analyst Commentary Recent Street research provides a mix of optimism and caution around Pennant Group, with updated targets and ratings reflecting changing views on reimbursement, valuation, and sector risk.ナラティブ更新 • Dec 16
PNTG Will Balance Reimbursement Upside Against Policy And Margin Execution Risks
Pennant Group's analyst price target has been raised from $28 to $30 per share, as analysts highlight upside from potential home health reimbursement improvements despite conservative base case assumptions. Analyst Commentary While the latest target increase underscores growing optimism around home health reimbursement, not all market observers share an unequivocally bullish stance.分析記事 • Aug 09
The Pennant Group, Inc. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
NasdaqGS:PNTG 1 Year Share Price vs Fair Value Explore Pennant Group's Fair Values from the Community and select yours...分析記事 • Jul 17
Earnings Tell The Story For The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong...分析記事 • Jun 28
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • May 16
Pennant Group's (NASDAQ:PNTG) Earnings Are Weaker Than They Seem
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock was strong after they recently reported robust earnings. However, our...分析記事 • Apr 15
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 33% Discount?
Key Insights Pennant Group's estimated fair value is US$38.66 based on 2 Stage Free Cash Flow to Equity Pennant Group...分析記事 • Mar 01
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...分析記事 • Dec 21
Why Investors Shouldn't Be Surprised By The Pennant Group, Inc.'s (NASDAQ:PNTG) P/E
With a price-to-earnings (or "P/E") ratio of 44.5x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...分析記事 • Nov 14
Investors Shouldn't Be Too Comfortable With Pennant Group's (NASDAQ:PNTG) Earnings
Unsurprisingly, The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock price was strong on the back of its healthy earnings...分析記事 • Nov 12
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 34% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pennant Group fair value estimate is US$50.94 Current share...分析記事 • Oct 06
Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
新しいナラティブ • Sep 16
Critical Acquisitions And Leadership Drive Remarkable Growth In Home Health Sector
Emphasis on expansion and acquisitions, such as the Muir Home Health joint venture, aims to significantly boost revenue and market share.分析記事 • Sep 14
Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 53.9x might make it look like a strong...分析記事 • Aug 26
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • May 14
Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...収支内訳
収支内訳
Pennant Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 26 | 1,102 | 32 | 141 | 0 |
| 31 Mar 26 | 1,023 | 30 | 136 | 0 |
| 31 Dec 25 | 948 | 30 | 130 | 0 |
| 30 Sep 25 | 847 | 27 | 122 | 0 |
| 30 Jun 25 | 799 | 27 | 114 | 0 |
| 31 Mar 25 | 748 | 25 | 107 | 0 |
| 31 Dec 24 | 695 | 23 | 102 | 0 |
| 30 Sep 24 | 652 | 21 | 97 | 0 |
| 30 Jun 24 | 612 | 19 | 88 | 0 |
| 31 Mar 24 | 575 | 16 | 88 | 0 |
| 31 Dec 23 | 545 | 13 | 84 | 0 |
| 30 Sep 23 | 524 | 13 | 81 | 0 |
| 30 Jun 23 | 502 | 13 | 77 | 0 |
| 31 Mar 23 | 486 | 7 | 77 | 0 |
| 31 Dec 22 | 473 | 7 | 78 | 0 |
| 30 Sep 22 | 460 | 1 | 80 | 0 |
| 30 Jun 22 | 454 | -3 | 83 | 0 |
| 31 Mar 22 | 448 | 3 | 83 | 0 |
| 31 Dec 21 | 440 | 3 | 81 | 0 |
| 30 Sep 21 | 436 | 9 | 81 | 0 |
| 30 Jun 21 | 422 | 12 | 81 | 0 |
| 31 Mar 21 | 405 | 14 | 77 | 0 |
| 31 Dec 20 | 391 | 16 | 75 | 0 |
| 30 Sep 20 | 372 | 8 | 71 | 0 |
| 30 Jun 20 | 362 | 5 | 64 | 0 |
| 31 Mar 20 | 352 | 4 | 64 | 0 |
| 31 Dec 19 | 339 | 3 | 61 | 0 |
| 30 Sep 19 | 324 | 10 | 57 | 0 |
| 30 Jun 19 | 309 | 13 | 55 | 0 |
| 31 Mar 19 | 296 | 14 | 51 | 0 |
| 31 Dec 18 | 286 | 16 | 49 | 0 |
| 31 Dec 17 | 251 | 10 | 46 | 0 |
| 31 Dec 16 | 217 | 8 | 41 | 0 |
質の高い収益: PNTGは 高品質の収益 を持っています。
利益率の向上: PNTGの現在の純利益率 (2.9%)は、昨年(3.4%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: PNTGの収益は過去 5 年間で年間39.2%増加しました。
成長の加速: PNTGの過去 1 年間の収益成長率 ( 20.5% ) は、5 年間の平均 ( 年間39.2%を下回っています。
収益対業界: PNTGの過去 1 年間の収益成長率 ( 20.5% ) はHealthcare業界20.5%を上回りました。
株主資本利益率
高いROE: PNTGの 自己資本利益率 ( 9.5% ) は 低い とみなされます。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/16 22:38 |
| 終値 | 2026/08/14 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
The Pennant Group, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Brian Tanquilut | Jefferies LLC |
| Michael Wiederhorn | Oppenheimer & Co. Inc. |
| Benjamin Hendrix | RBC Capital Markets |